𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The prognostic significance of sialyl-tn Antigen in women treated with breast carcinoma treated with adjuvant chemotherapy

✍ Scribed by Anita Yeomans Kinney; Aysegul Sahin; Sally W. Vernon; Ralph F. Frankowski; John F. Annegers; Gabriel N. Hortobagyi; Aman U. Buzdar; Debra K. Frye; Kapil Dhingra


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
116 KB
Volume
80
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Results

. Forty-eight (23%) of the 207 specimens demonstrated high STn staining ter, Houston, Texas.

(ΓΊ25% cells were immunoreactive). During a median follow-up of 5 years, high STn patients had worse disease free survival than low STn patients (55% vs. 74%,


πŸ“œ SIMILAR VOLUMES


Effect of adjuvant chemotherapy on outco
✍ Jean-Yves Pierga; Bernard Asselain; Michel Jouve; VΓ©ronique DiΓ©ras; Mathieu Cart πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 141 KB πŸ‘ 2 views

## BACKGROUND. The objective of the current study was to analyze the impact of adjuvant chemotherapy in comparison with other prognostic parameters on the outcome of a series of patients with breast carcinoma at time of metastatic recurrence. ## METHODS. Data from 1430 patients accrued in 8 pro

Long term follow-up of women treated wit
✍ Bahar Mikhak; Marianna Zahurak; Martin D. Abeloff; John H. Fetting; Nancy E. Dav πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 2 views

## Background: A phase ii study was performed evaluating the disease free and overall survival rates associated with a dose-intensive, 16-week, doxorubicin-based adjuvant chemotherapy regimen in women with breast carcinoma and > or = 10 involved axillary lymph nodes. ## Methods: Eligible patients

Long term follow-up of women with ductal
✍ Kimberly J. Van Zee; Laura Liberman; Billur Samli; Katherine N. Tran; Beryl McCo πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## BACKGROUND. Although in recent years there has been a dramatic increase in both the incidence of ductal carcinoma in situ (DCIS) and breast-conserving therapy for patients who have this disease, the optimal treatment for these patients remains controversial. Most data regarding outcomes have co